Contract development and manufacturing organizations (CDMOs) are reshaping pharmaceutical production, playing a pivotal role in supply chain stability and driving innovation.

In today’s fast-evolving environment, CDMOs help life sciences companies enhance speed, flexibility, and efficiency, which ultimately advances access to life-saving therapies. Norstella provides tailored insights, tools, and intelligence solutions to support this progress, empowering companies to make informed decisions and optimize their manufacturing partnerships.

This year at CPHI Milan, our team observed key industry trends, including innovations to strengthen supply chains and enhance sustainable practices. At Citeline’s (a Norstella company) 11th Annual Global Generics & Biosimilars Awards, we also celebrated excellence in the generics sector.

Following the conference, Andrea Charles, VP of custom content at Norstella, and Andrew Warmington, Citeline’s manufacturing editor, joined Izabela Chmielewska, managing editor of custom content, to discuss major takeaways – from the BIOSECURE Act’s influence on global operations to advancements in biomanufacturing. Together, they explored how Norstella and Citeline drive solutions to streamline the journey from pipeline to patient.